Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Gemtuzumab ozogamicin,"Acute myeloid leukaemia, favourable and intermediate-risk (AML-19 trial)",Gemtuzumab ozogamicin,,Community and Hospital,Oncology Agents and Immunosuppressants
